Leukemia Clinical Trials in Philadelphia

Showing 201-220 of 1,744 trials

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

NCT02392429

This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in the body. FLT is injected into the blood and builds up in cells that are dividing, including cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to earlier treatment.

Acute Myeloid Leukemia

National Cancer Institute (NCI)87 participantsStarted Apr 2016

Rochester, Minnesota, United States • St Louis, Missouri, United States • New York, New York, United States +8 more locations

RECRUITINGPhase 2< 1 mile

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Advanced Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more

National Cancer Institute (NCI)46 participantsStarted Apr 2018

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +337 more locations

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Leukemia Trials in Other Cities

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Improving Medical Decision Making for Older Patients With End Stage Renal Disease

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Other Conditions in Philadelphia